Prevención de la transmisión vertical y tratamiento de la infección por el virus de la inmunodeficiencia humana en la mujer embarazada

LB7. 60. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998;12:F241-7. 61. O Sullivan MJ, Scott G, Yasin S, Mitchell C, Scott W, Duthely M. Protease inhibitors: Is preterm delivery a risk? Am J Obstet Gynecol 1999;180(1S-II):105S. 62. Morris A, Zorrilla C, Vajaranant M, Dobles A, Cu-uvin S, Jones T, et al. A review of protease inhibitors use in 89 pregnancies. Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999;. Abstract 686. 63. Stek A, Khoury M, Kramer F, Homans J, Rother C, Kovacs A. Maternal and Infant Outcomes with Highly Active Antiretroviral Therapy During Pregnancy. Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999